CRISPR Therapeutics AG (CRSP)
Largest Insider Buys in Sector
CRSP Stock Price History Chart
CRSP Stock Performance
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product …
Insider Activity of CRISPR Therapeutics AG
Over the last 12 months, insiders at CRISPR Therapeutics AG have bought $0 and sold $13.77M worth of CRISPR Therapeutics AG stock.
On average, over the past 5 years, insiders at CRISPR Therapeutics AG have bought $0 and sold $48.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 54,922 shares for transaction amount of $1.37M was made by Vertex Pharmaceuticals (Europe) Ltd (10 percent owner) on 2018‑12‑27.
List of Insider Buy and Sell Transactions, CRISPR Therapeutics AG
| 2024-12-02 | Sale | Chief Executive Officer | 15,000 0.0175% | $55.10 | $826,565 | -12.55% | ||
| 2024-11-11 | Sale | Chief Executive Officer | 30,000 0.0356% | $55.62 | $1.67M | -10.12% | ||
| 2024-10-14 | Sale | Chief Executive Officer | 4,293 0.005% | $46.28 | $198,680 | +2.45% | ||
| 2024-10-14 | Sale | General Counsel and Secretary | 1,089 0.0013% | $46.28 | $50,399 | +2.45% | ||
| 2024-06-21 | Sale | Chief Operating Officer | 3,366 0.0036% | $56.09 | $188,799 | -13.59% | ||
| 2024-04-15 | Sale | Chief Executive Officer | 19,582 0.0235% | $59.91 | $1.17M | -13.53% | ||
| 2024-03-15 | Sale | Chief Executive Officer | 20,000 0.0236% | $72.48 | $1.45M | -27.33% | ||
| 2024-03-15 | Sale | Chief Financial Officer | 3,524 0.0042% | $72.69 | $256,160 | -27.33% | ||
| 2024-03-12 | Sale | Chief Executive Officer | 4,583 0.0054% | $74.44 | $341,159 | -29.07% | ||
| 2024-03-12 | Sale | General Counsel and Secretary | 1,146 0.0013% | $74.44 | $85,308 | -29.07% | ||
| 2024-03-11 | Sale | Chief Executive Officer | 9,802 0.0119% | $78.26 | $767,105 | -30.29% | ||
| 2024-03-11 | Sale | General Counsel and Secretary | 2,801 0.0034% | $78.26 | $219,206 | -30.29% | ||
| 2024-02-20 | Sale | Chief Executive Officer | 6,370 0.0081% | $79.67 | $507,498 | -30.70% | ||
| 2024-02-20 | Sale | General Counsel and Secretary | 1,913 0.0024% | $79.67 | $152,409 | -30.70% | ||
| 2024-02-15 | Sale | Chief Executive Officer | 20,000 0.0256% | $80.36 | $1.61M | -35.18% | ||
| 2024-01-29 | Sale | Chief Executive Officer | 50,000 0.0582% | $60.51 | $3.03M | -15.75% | ||
| 2024-01-16 | Sale | Chief Executive Officer | 20,000 0.0249% | $62.50 | $1.25M | -12.23% | ||
| 2023-05-30 | Sale | Chief Executive Officer | 25,000 0.0319% | $64.88 | $1.62M | -11.56% | ||
| 2023-04-25 | Sale | Chief Executive Officer | 25,000 0.033% | $50.67 | $1.27M | +19.36% | ||
| 2023-03-29 | Sale | Chief Executive Officer | 25,000 0.0316% | $44.46 | $1.11M | +27.58% |
Insider Historical Profitability
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 5632802 6.5994% | $40.72 | 1 | 0 | +77.06% |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 6.3043% | $40.72 | 4 | 0 | +63.29% |
| CELGENE CORP /DE/ | 10 percent owner | 4173019 4.8891% | $40.72 | 1 | 21 | +31.44% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 3220627 3.7733% | $40.72 | 1 | 0 | +31.44% |
| George Simeon | director | 3220627 3.7733% | $40.72 | 1 | 0 | +31.44% |
Institutional Investor Ownership
| ARK Investment Management LLC | $555.98M | 9.61 | 8.16M | -4.44% | -$25.84M | 1.92 | |
| Capital International Investors | $534.17M | 9.23 | 7.84M | +27.75% | +$116.05M | 0.11 | |
| Nikko Asset Management Americas Inc | $222.7M | 3.85 | 3.27M | -3% | -$6.88M | 1.67 | |
| Sumitomo Mitsui Trust Holdings | $222.8M | 3.85 | 3.27M | -3% | -$6.88M | 0.15 | |
| T Rowe Price Investment Management Inc | $184.33M | 3.19 | 2.7M | -25.11% | -$61.81M | 0.11 |